Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II

Blood

Volumn 111, Issue 8, 2008, Pages 4118-4125

  He, Li ^a   Giri, Tusar K ^a   Vicente, Cristina P ^b   Tollefsen, Douglas M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DERMATAN SULFATE; HEPARIN COFACTOR II; HISTIDINE; LYSINE; CHONDROITIN ABC LYASE; FIBRINOLYTIC AGENT; HEPARAN SULFATE; MUTANT PROTEIN; RECOMBINANT PROTEIN; THROMBIN;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY INJURY; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOGENESIS; THROMBUS; VASCULAR ENDOTHELIUM; ANIMAL; C57BL MOUSE; CAROTID ARTERY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; FEMALE; HUMAN; LIGHT; MALE; METABOLISM; PATHOLOGY; RADIATION EXPOSURE; SWINE; THROMBOSIS; TIME;

ANIMALS; CAROTID ARTERIES; CHONDROITIN LYASES; DERMATAN SULFATE; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN COFACTOR II; HEPARITIN SULFATE; HUMANS; LIGHT; MALE; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; SWINE; THROMBIN; THROMBOSIS; TIME FACTORS;

EID: 43249130447     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-127928     Document Type: Article

References (49)

1. Mann KG. Thrombin formation. Chest. 2003;124:4S-10S.
2. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800-1814.
3. Bock S. Antithrombin III and heparin cofactor II. In: Colman R. Marder V, Clowes A, George J, Goldhaber S, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:235-248.
4. Tollefsen D, Zhang L. Heparin and vascular proteoglycans. In: Colman R, Marder V, Clowes A, George J. Goldhaber S, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:271-283.
5. Tollefsen DM. Antithrombin deficiency. In: Scriver C, Beaudet A, Sly W, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:4455-4471.
6. Ishiguro K, KojimaT, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest. 2000;106:873-878.
7. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 1983;258:6713-6716.
8. McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem. 1987;262:169-175.
9. Whinna HC, Choi HU, Rosenberg LC, Church FC. Interaction of heparin cofactor II with biglycan and decorin. J Biol Chem. 1993;268:3920-3924.
10. Tollefsen DM. Heparin cofactor II deficiency. Arch Pathol Lab Med. 2002;126:1394-1400.
11. Aihara K, Azuma H, Takamori N, et al. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation. 2004;109:2761-2765.
12. Schillinger M, Exner M, Sabeti S, et al. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Thromb Haemost. 2004;92:1108-1113.
13. Takamori N, Azuma H, Kato M, et al. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation. 2004;109:481-486.
14. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109:213-219.
15. Vicente CP He L, Pavão MS, Tollefsen DM. Antithrombotic activity of dermatan sulfate in heparin cofactor ll-deficient mice. Blood. 2004;104:3965-3970.
16. Teien AN, Abildgaard U, Höök M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res. 1976;8:859-867.
17. Colwell NS, Grupe MJ, Tollefsen DM. Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions. Biochim Biophys Acta. 1999;1431:148-156.
18. Tollefsen DM, Majerus DW. Blank MK. Heparin cofactor II: purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem. 1982;257:2162-2169.
19. Giri TK, Ahn CW, Wu KK, Tollefsen DM. Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2005;25:2689-2690.
20. Giri TK, Tollefsen DM. Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood. 2006;107:2753-2758.
21. Michelacci YM, Dietrich CP. A comparative study between a chondroitinase B and a chondroitinase AC from Flavobacterium heparinum: isolation of a chondroitinase AG-susceptible dodecasaccharide from chondroitin sulphate B. Biochem J. 1975;151:121-129.
22. Oike Y, Kimata K, Shinomuram T, Suzuki S, Takahashi N, Tanabe K. A mapping technique tor probing the structure of proteoglycan core molecules. J Biol Chem. 1982;257:9751-9758.
23. Linker A, Hovingh P. Isolation and characterization of oligosaccharides obtained from heparin by the action of heparinase. Biochemistry. 1972;11:563-568.
24. Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM. Heparin cofactor IIOslo: mutation of Arg-189 to His decreases the affinity for dermatan sulfate. J Biol Chem. 1989;264:5128-5133.
25. Whinna HC, Blinder MA, Szewczyk M, Tollefsen DM, Church FC. Role of lysine 173 in heparin binding to heparin cofactor II. J Biol Chem. 1991;266:8129-8135.
26. Zhang GS, Mehringer JH, Van Deerlin VM, Kozak CA, Tollefsen DM. Murine heparin cofactor II: purification. cDNA sequence, expression, and gene structure. Biochemistry. 1994;33:3632-3642.
27. Couchman JR, Caterson B, Christner JE, Baker JR. Mapping by monoclonal antibody detection of glycosaminoglycans in connective tissues. Nature. 1984;307:650-652.
28. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol. 1992;119:961-975.
29. Tovar AM, de Mattos DA, Stalling MP Sarcinelli-Luz BS, Nazareth RA, Mourão PA. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta. 2005;1740:45-53.
30. Sié P, Ofosu F, Fernandez F, Buchanan MR, Petitou M, Boneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol. 1986;64:707-714.
31. Halldórsdóttir AM, Zhang L, Tollefsen DM. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate. Glycobiology. 2006;16:693-701.
32. Maimone MM, Tollefsen DM. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem. 1990;265:18263-18271.
33. Matsuno H, Uematsu T, Nagashima S, Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods. 1991;25:303-317.
34. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087-1097.
35. Fleck RA, Rao LV. Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res. 1990;59:421-437.
36. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839-2843.
37. Hatton MW, Hoogendoorn H, Southward SM, Ross B, Blajchman MA. Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. Am J Physiol. 1997;272:E824-E831.
38. Sié P, Dupouy D, Pichon J, Boneu B. Turnover study of heparin cofactor II in healthy man. Thromb Haemost. 1985;54:635-638.
39. Sié P, Lansen J, Lacheretz F, Verschuere B, Boneu B. Comparative turn-over of heparin cofactor II and antithrombin III in baboons: influence of heparin and pentosan polysulfate administration. Thromb Haemost. 1986;56:302-307.
40. Le DT Borgs P, Toneff TW, Witte MH, Rapaport SI. Hemostatic factors in rabbit limb lymph: relationship to mechanisms regulating extravascular coagulation. Am J Physiol. 1998;274:H769-H776.
41. Tuma PL, Hubbard AL. Transcytosis: crossing cellular barriers. Physiol Rev. 2003;83:871-932.
42. Cooper ST, Neese LL, DiCuccio MN, Liles DK, Hoffman M, Ghurch FC. Vascular localization of the heparin-binding serpins antithrombin, heparin cofactor II, and protein C inhibitor. Clin Appl Thrombosis/Hemostasis. 1996;2:185-191.
43. Dewerchin M, Hérault JP Wallays G, et al. Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. Circ Res. 2003;93:1120-1126.
44. Lane DA, Kunz G, Olds RJ, Thein SL. Molecular genetics of antithrombin deficiency. Blood Rev. 1996:10:59-74.
45. HajMohammadi S, Enjyoji K, Princivalle M, et al. Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. J Clin Invest. 2003;111:989-999.
46. Xia G, Chen J, Tiwari V, et al. Heparan sulfate 3-O-suIfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1. J Biol Chem. 2002;277:37912-37919.
47. Scully MF, Ellis V Kakkar VV. Heparan sulphate with no affinity for antithrombin III and the control of haemostasis. REBS Lett. 1988;241:11-14.
48. Aihara K, Azuma H, Akaike M, et al. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor ll-deficient mice. J Clin Invest. 2007;117:1514-1526.
49. Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor ll-deficient mice. Blood. 2007;110:4261-4267.